BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 35771575)

  • 21. Racial/Ethnic and Socioeconomic Disparities in Management of Incident Paroxysmal Atrial Fibrillation.
    Eberly LA; Garg L; Yang L; Markman TM; Nathan AS; Eneanya ND; Dixit S; Marchlinski FE; Groeneveld PW; Frankel DS
    JAMA Netw Open; 2021 Feb; 4(2):e210247. PubMed ID: 33635328
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Disparities in Care Management During Terminal Hospitalization Among Adults With Metastatic Cancer From 2010 to 2017.
    Deeb S; Chino FL; Diamond LC; Tao A; Aragones A; Shahrokni A; Yerramilli D; Gillespie EF; Tsai CJ
    JAMA Netw Open; 2021 Sep; 4(9):e2125328. PubMed ID: 34550384
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Survival disparities in non-small cell lung cancer by race, ethnicity, and socioeconomic status.
    Tannenbaum SL; Koru-Sengul T; Zhao W; Miao F; Byrne MM
    Cancer J; 2014; 20(4):237-45. PubMed ID: 25098282
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Racial/Ethnic Disparities Associated With Initial Hemodialysis Access.
    Zarkowsky DS; Arhuidese IJ; Hicks CW; Canner JK; Qazi U; Obeid T; Schneider E; Abularrage CJ; Freischlag JA; Malas MB
    JAMA Surg; 2015 Jun; 150(6):529-36. PubMed ID: 25923973
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association of insurance status and ethnicity with cancer stage at diagnosis for 12 cancer sites: a retrospective analysis.
    Halpern MT; Ward EM; Pavluck AL; Schrag NM; Bian J; Chen AY
    Lancet Oncol; 2008 Mar; 9(3):222-31. PubMed ID: 18282806
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Changes in Racial and Ethnic Disparities in Access to Care and Health Among US Adults at Age 65 Years.
    Wallace J; Jiang K; Goldsmith-Pinkham P; Song Z
    JAMA Intern Med; 2021 Sep; 181(9):1207-1215. PubMed ID: 34309621
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunotherapy Treatment Disparities: A Texas Cancer Registry Analysis of Patients with Cutaneous Melanoma.
    Ramirez F; Alvarado L; Dwivedi A; Chacon J
    J Immigr Minor Health; 2024 Feb; 26(1):23-33. PubMed ID: 37615821
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differences in Receipt of Immunotherapy Treatment Among Patients With Head and Neck Cancer.
    Ramkumar SP; Bhardwaj A; Patel A; Seetharaman K; Christman A; Amondikar N; Abouelella DK; Hussaini AS; Barnes JM; Adjei Boakye E; Watts TL; Osazuwa-Peters N
    JAMA Otolaryngol Head Neck Surg; 2023 Oct; 149(10):912-918. PubMed ID: 37651149
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association of Treatment Inequity and Ancestry With Pancreatic Ductal Adenocarcinoma Survival.
    Heller DR; Nicolson NG; Ahuja N; Khan S; Kunstman JW
    JAMA Surg; 2020 Feb; 155(2):e195047. PubMed ID: 31800002
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association of the Comprehensive Care for Joint Replacement Model With Disparities in the Use of Total Hip and Total Knee Replacement.
    Thirukumaran CP; Kim Y; Cai X; Ricciardi BF; Li Y; Fiscella KA; Mesfin A; Glance LG
    JAMA Netw Open; 2021 May; 4(5):e2111858. PubMed ID: 34047790
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Racial/Ethnic Disparities in Ophthalmology Clinical Trials Resulting in US Food and Drug Administration Drug Approvals From 2000 to 2020.
    Berkowitz ST; Groth SL; Gangaputra S; Patel S
    JAMA Ophthalmol; 2021 Jun; 139(6):629-637. PubMed ID: 33885724
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunotherapy Utilization Among Patients With Metastatic NSCLC: Impact of Comorbidities.
    Zhang D; Tailor TD; Kim C; Atkins MB; Braithwaite D; Akinyemiju T
    J Immunother; 2021 Jun; 44(5):198-203. PubMed ID: 33758148
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical Trial Evidence Supporting US Food and Drug Administration Approval of Novel Cancer Therapies Between 2000 and 2016.
    Ladanie A; Schmitt AM; Speich B; Naudet F; Agarwal A; Pereira TV; Sclafani F; Herbrand AK; Briel M; Martin-Liberal J; Schmid T; Ewald H; Ioannidis JPA; Bucher HC; Kasenda B; Hemkens LG
    JAMA Netw Open; 2020 Nov; 3(11):e2024406. PubMed ID: 33170262
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Assessment of Social Vulnerability in Pediatric Head and Neck Cancer Care and Prognosis in the United States.
    Fei-Zhang DJ; Chelius DC; Patel UA; Smith SS; Sheyn AM; Rastatter JC
    JAMA Netw Open; 2023 Feb; 6(2):e230016. PubMed ID: 36800183
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Racial disparities and treatment trends in a large cohort of elderly black and white patients with nonsmall cell lung cancer.
    Hardy D; Liu CC; Xia R; Cormier JN; Chan W; White A; Burau K; Du XL
    Cancer; 2009 May; 115(10):2199-211. PubMed ID: 19365824
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Trends in Use of Next-Generation Sequencing in Patients With Solid Tumors by Race and Ethnicity After Implementation of the Medicare National Coverage Determination.
    Sheinson DM; Wong WB; Meyer CS; Stergiopoulos S; Lofgren KT; Flores C; Adams DV; Fleury ME
    JAMA Netw Open; 2021 Dec; 4(12):e2138219. PubMed ID: 34882180
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Race/ethnicity and advanced stage of renal cell carcinoma in adults: results from surveillance, epidemiology, and end results program 2007-2015.
    Dobyns AC; Coutelle NA; Suthumphong CY; Rodriguez PE; Castro G; Varella MH
    Eur J Cancer Prev; 2022 Mar; 31(2):172-177. PubMed ID: 34115692
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Economic Burden of Checkpoint Inhibitor Immunotherapy for the Treatment of Non-Small Cell Lung Cancer in US Clinical Practice.
    Nesline MK; Knight T; Colman S; Patel K
    Clin Ther; 2020 Sep; 42(9):1682-1698.e7. PubMed ID: 32747004
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.